3-Substituted-5-aminomethyl-6-carbethoxy(oxazino {8 5{40 ,6{40 {0 E indoles).

ABSTRACT

A compound of the formula   WHEREIN N is pyrrolidino, piperidino or piperazino N&#39;&#39;substituted with isopropylamino carbonyl methyl, pyrrolidino carbonyl methyl or ethylacetate, and R is a hydrocarbon radical having 1 to 6 carbon atoms, optionally substituted with a hydroxyl or tertiary amino group. The compounds are prepared by reacting 2-carbethoxy-3-substituted-5-hydroxy indole with formaldehyde and an amine of the formula RNH2. The compounds possess analgesic, antiinflammatory, hypotensive, antihypertensive, vasodilatatory, respiratory analeptic, sedative anticonvulsant, anxiolytic, bronchodilatatory, spasmolytic and diuretic properties.

United States Patent Fauran et al.

[ 51 May 13, 1975 S-SUBSTITUTED-S-AMINOMETHYL-6-CAR- BETHOXY(0XAZINO [5,6' E INDOLES).

inventors: Claude Fauran; Michel J. Turin;

Gerard J. Huguet; Guy M. Raynaud, all of Paris; Bernard M. Pourrias, Meudon La Foret, all of France Assignee: Delalande S.A., Courbevoie, France Filed. May 24, 1973 Appl. No.: 363,535

Foreign Application Priority Data June 8, 1972 France .4 72.20644 US. Cl.. 260/244 R; 260/268 BC; 260/293.6l;

260/326.l4; 424/248 Int. Cl C07d 87/06 Field of Search 260/244 R, 268 TR Primary Examiner-Donald G. Daus Assistant ExaminerJose Tovar Attorney, Agent, or Firm-Woodhams, Blanchard &

Flynn [57] ABSTRACT A compound of the formula CHz--N \x wherein N is pyrrolidino. piperidino or piperazino N'- substituted with isopropylamino carbonyl methyl, pyrrolidino carbonyl methyl or ethylacetate, and R is a hydrocarbon radical having I to 6 carbon atoms, optionally substituted with a hydroxyl or tertiary amino group. The compounds are prepared by reacting 2- carbethoxy-3-substituted-5-hydroxy indole with formaldehyde and an amine of the formula RNH The compounds possess analgesic, antiinflammatory, hypotensive, antihypertensive, vasodilatatory, respiratory analeptic, sedative anticonvulsant, anxiolytic, bronchodilatatory, spasmolytic and diuretic properties.

14 Claims, No Drawings 3-SUBSTITUTED-S-AMINOMETHYL-6-CARBE- THOXY(OXAZINO [,6' E INDOLES).

The present invention relates to novel 3-substituted -5-aminomethyl-6-carbethoxy loxazino(5',6'e) indoles], their process of preparation and their therapeutic applicationv The compounds according to the invention correspond to the general formula:

in which:

with two moles of formaldehyde and one mole ofa primary amine of formula:

R N H (Ill) the radicals:

and R having in these formulas the same signification as in formula (l) The starting compounds corresponding to formula (III) may be obtained according to the procedure described by M. JULIA and J. Y. LALLEMAND in CR. Acad, Sc Paris, t 267 (1506), that is to say by operating, in a first stage, an aminomethylation reaction (Mannich reaction) on 5-benzyloxy-2ethoxycarbonyl indole of formula:

l H (IV) with the aid of formol and an amine of formula (V):

in which has the same signification as in formula (I), and then, in a second stage, to debenzylate the Mannich base so obtained of formula:

The following preparation is given by way of example to illustrate the invention.

EXAMPLE 3-lsopropyl-5-[4"-(isopropylaminocarbonylmethyl) piperazinomethyl]-6-ethoxycarbonyl [2H 4 H oxazino (5',6'e) indole].

Code No: 71234 7c.c. of an aqueous solution of 40% formaldehyde is dissolved in cc of alcohol, and the mixture is cooled to 10C. 4g of isopropylamine in solution in 20 cc. of alcohol is then progressively added thereto Then 16g of 3-(4-isopropylaminocarbonylmethyl-l piperazinomethyl)-2-carbethoxy-5-hydroxy indole is introduced into the mixture. The mixture is then refluxed.

The product which precipitates is dried after cooling, and then recrystallised from acetone Melting point 204"C Yield 43% Empirical formula C H N 0, Elementary analysis:

C H N Calculated (14,30 8. It] I442 Found "/i' 64,20 Kl) I453 The compounds listed in the following Table l have been prepared by the same operational procedure TABLE 1 --H-C111-N l \V/ 1 N GOUC II5 Elementary analysis, percent 7 Alclec- Molti11 1 Calculated Found (0111 N 2. Empirical ular point, Yield. N1). 1 R formula weight L percvnt C ll N C II N 7127.... C11H11 CzaHMNaOa 425.55 H12 3H 70.55 8.21! .1188 70.4!) 8.21 l0.(]T

?l28.. /Cl 1 (211113131101 335.111 15 .1 17 68.54 11.11 10.111) 68.33 8.35 11.1111

711ss. C -H.-, 0111117N101 351.11 11111 31 117.20 7.111 11.711 117.22 7.513 11.81]

71111 1... /cu1 c111111N o1 371.111 150 113 117.110 7.87 11.31 117.1111 7. .17 11.17

71513.... c111 -(c1I111N(c =11 11 c ummo, 512.711 2111 1 1 111.111 11.51 11.111 111.211 11.117 15.113

N N omcommn 7151111.. 0 1111 C:1ll1;1N ()1 525.117 233 113 111.211 13.32 110.111 11. 13.12 715111. -cn1 c11 1311, 01111 1110, 1113.51 2117 15 115.17 771 14.48 111.311 7.711 11.11

71531... ((ll1l N((. ll 0 11 111 11. 551.71 111 1 17 111.115 11.311 15.15 111.1111 11.11 15.1111

N NCH1CUN N N-culcoucnr.

71512. 11114-11 011; (1;ll N U 1711.55 153 53 113.51 7211 11.111 113.112 7.35 11.71 71551 1 11111011 1 1 111101 111 171.51 113 31 1111.71 722 11.111 1111.57 7211 11.111

The compounds of formula (I) have been studied on TABLE 1] animals in the laboratory and have been shown to pos- SCSS analgesic, antiinflammatory, hypotensive, antihy- 55 Code No. of Dose administered Percentage reduction pertensive, vasodilatatory, respiratory analeptic, seda- Compound (mg/kg/PO) $222222: 21 tive. anticonvulsivant, anxiolytic, bronchodilatatory, spasmolytic and diuretic properties. 7137 100 7128 100 7188 75 l. Anal esic r0 erties 71188 50 70 g p p 60 7111 19 100 60 The compounds of formula (I), administered by oral 5 20 611 means to the mouse, are capable of reducing the num- 5 m8 ber of painful stretchings caused by the intraperitoneal 71235 25 70 injection of acetic acid. 45 71512 30 80 By way of examples, the results obtained with dlffer- 65 71539 ent compounds of formula (I) are listed in the following Table I].

2. Antiinflammatory properties These properties are shown by a diminution of the local oedema caused by the sub-plantar injection of a phlogogenic agent, such as carraghenin, in the rat following the oral administration of compounds of formula (1).

By way of examples, the results obtained with different compounds of formula (1) are given in the following Table 111:

TABLE 111 Code No. of Dose administered Percentage reduction of compound (mg/kg/PO) sub-p1antar oedema tested 3. Hypotensive properties Administered by intraveinous means to the rat, the compounds of formula (1) cause a lowering of the arterial pressure.

By way of example, the following Table IV gives the results obtained with different compounds of formula TABLE IV Code No. Dose administ- Percentage Duration of of compound ered (mg/kg/IV) reduction of effect tested arterial (rnn) pressure 7127 l E 45 40 7128 1 E 20 71188 1 E 65 30 71 189 1 E 50 30 71236 1 30 30 71519 2 E 65 40 4. Antihypertensive properties The compounds of formula (1) administered orally into a hypertensive rat, are capable of reducing the sys tolic arterial pressure.

By way of examples, the results obtained by administration of different compounds of formula (I), are given in the following Table V:

TABLE V Code No. of Dose administered Percentage of animals compound (mg/kg/PO) having arterial pressure tested which is brought back to normal (3%) 5. Vasodilatatory properties The compounds of formula (1) are capable of augmenting the flow of the coronary vessels of the isolated heart of a guinea-pig, when said compounds are added in the perfusion liquid of said organ.

By way of example Table VI indicates the results obtained with different compounds of formula (1).

TABLE V1 Dose adminsitered in the perfusion liquid (#g/m Code no. of compound tested Percentage augmentation of flow of isolated heart 6. Respiratory analeptic properties The compounds of formula (1), administered by intraveinous or intraduodenal means to the anaesthetised guinea-pig, are capable of opposing the respiratory depression caused by morphine.

By way of example, the results obtained with different compounds of formula (I) are given in the following It is to be noted, as well, that administration of IOOmg/kg/ID of the compound of Code No. 71554 causes, in the anaesthetised guinea-pig, a percentage augmentation of the amplitude of respiratory movements equal to 45%.

7. Sedative properties The compounds of formula (1), administered by oral means to the mouse, reduce the number of explorations in the evasion enclosure.

By way of example, the administration of mg/kg/PO of the compounds of code Nos. 7127 and 71541 produced a percentage reduction of the number of explorations in the evasion enclosure equal to 35% and 30% respectively.

8. Anticonvulsivant and anxiolytic properties The compounds of formula (I), possess the property of inhibiting by oral means the mortality caused in a mouse by the administration of cardiazol.

By way of examples, the administration of 100mg/kg/PO of the compounds of code Nos. 7127 and 71542 produce a protection of 40% against the lethality of cardiazol.

9. Bronchodilatatory properties Injected by intraveinous means, the compounds of formula (I) are capable of opposing the bronchoconstriction caused in the guinea-pig by the intraveinous injection of acetylcholine, and evaluated by the Konzett method.

By way of examples, the results obtained with different compounds of formula (1) are listed in the following Table V111.

TABLE Vlll Code No. of Dose administered Percentage inhibition compound (ug/kg/lV) of bronc hoconstriction tested 7 l 188 500 I H206 2 5U 10. Spasmolytic properties The compounds of formula (I) introduced in the conserving medium, are capable of opposing the contractural action of barium chloride on the isolated duode num of the rat. This activity is evaluated by taking papaverine as standard.

By way of examples, the activity of the compounds of code Nos. H 190. 7l534 and 71541 is equal respec tively to /2, 166 and V2 that of papaverine.

l l. Diuretic properties The compounds of formula (I), administered by oral means to the mouse simultaneously with a volume of lml of an isotonic solution of sodium chloride per 25g. of the corporeal weight of the mouse, are capable of provoking an augmentation of the volume of urine emitted by reference to control animals, the volume being measured for 4 hours following administration.

By way of example, the following Table lX gives the results obtained with different compounds of formula TABLE IX Code No. of Dose administered Percentage augmentcompound (mg/kg/PO] ation of urinary tested elimination (kl 7127 50 718B 50 l! 7] I89 20 50 From the doses indicated above and the results listed in the following Table X, it can be seen that the difference between the pharmacologically active dose and the lethal dose is sufficiently great to permit the compounds of formula (I) to be utilised in therapeutics.

The compounds of formula (I) are useful in the treatment of various pains. especially inflammatory pains, hypertensions, circulatory insufficiencies. respiratory insufficiencies. anxieties, visceral spasms. asthma and oedemns.

They may be administered by oral means in the form of tablets. dragees and gelules containing to 400 mg of active ingredient (l to 5 times a day) and by rectal means in the form of suppositories containing 25 to 250 mg of active ingredient (l or 2 times a day).

Accordingly. the present invention relates to a thera- 5 peutic composition comprising a compound of the general formula (I) together with a therapeuticallyacceptable carrier.

What we claim is:

l. A compound having the formula i ll wherein R is alkyl having l to 6 carbon atoms, allyl. cyclohexyl, diethylamino ethyl or B-hydroxyethyl, and

I "N N N '1izco-N inc cn 25 l n N-(ll:-U()--- N or N N CllzCUUFilli.

\ V g g 2. A compound as claimed in claim 1, in which r. Wig cii. I. l

\ 15 -N N--(lI -Lu Nl1- (.]1

3. A compound as claimed in claim 1, in which is -i( N-cit -co-ii i l 40 4. A compound as claimed in claim 1, in which is -N N( 11 (JUUC lls 5. A compound as claimed in claim 1 in which R is ethyl, isopropyl, allyl or cyclohexyl.

6. A compound as claimed in claim 1 in which R is diethylamino ethyl radical or a B-hydroxylethyl 7. A compound as claimed in claim 1, in which 4N is N/ i L i 8. A compound as claimed in claim 7, in which R is ethyl.

9. A compound as claimed in claim 7, in which R is iso-propyl.

10. A compound as claimed in claim 7, in which R is allyl.

11. A compound as claimed in claim 7, in which R is cyclohexyl.

12. A compound as claimed in claim 1, in which R is isopropyl and V/ N is N N tlht)l\ inc-fill l ("in 13. A compound as claimed in claim 1, in which W s is s V 14. A compound as claimed in claim 13. in which R is ethyl. 

1. A COMPOUND HAVING THE FORMULA
 2. A compound as claimed in claim 1, in which
 3. A compound as claimed in claim 1, in which
 4. A compound as claimed in claim 1, in which
 5. A compound as claimed in claim 1 in which R is ethyl, isopropyl, allyl or cyclohexyl.
 6. A compound as claimed in claim 1 in which R is diethylamino ethyl radical or a Beta -hydroxylethyl.
 7. A compound as claimed in claim 1, in which
 8. A compound as claimed in claim 7, in which R is ethyl.
 9. A compound as claimed in claim 7, in which R is iso-propyl.
 10. A compound as claimed in claim 7, in which R is allyl.
 11. A compound as claimed in claim 7, in which R is cyclohexyl.
 12. A compound as claimed in claim 1, in which R is isopropyl and
 13. A compound as claimed in claim 1, in which
 14. A compound as claimed in claim 13, in which R is ethyl. 